ReviewCurrent rheumatology reports2016
Biological Therapy-Induced Systemic Vasculitis.
Review in Current rheumatology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Certolizumab-Induced Urticarial Vasculitis: A Case Report.Current drug safety · 2026Article
- IgA vasculitis induced by tumor necrosis factor-α antagonists: clinical features, diagnosis and management.Archives of dermatological research · 2025Article
- Comparative risk of systemic autoimmune diseases in juvenile idiopathic arthritis treated with TNF-α or IL-6 inhibitors: a real-world cohort study.Frontiers in immunology · 2025Article
- Rheumatoid Vasculitis in Modern Era: A Case Report and Comprehensive Literature Review.Cureus · 2024Article
- Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement.BMC nephrology · 2023Article
- Atypical Immunoglobulin A Vasculitis in a Pediatric Patient With Ulcerative Colitis.ACG case reports journal · 2023Article
- Spectrum of Large- and Medium-Vessel Vasculitis in Adults: Neoplastic, Infectious, Drug-Induced, Autoinflammatory, and Primary Immunodeficiency Diseases.Current rheumatology reports · 2022Review
- Vasculitis induced by biological agents used in rheumatology practice: A systematic review.Archives of rheumatology · 2022Review
- Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis.Chinese medical journal · 2019Review
- Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace.Current rheumatology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of biologics has been associated with the paradoxical development of biologics-induced autoimmune diseases. The purpose of this review was to describe the key immunopathogenic mechanisms involved in the development of these conditions, and to discuss the clinical and laboratory characteristics usually described in the medical literature, reviewing case reports as well as records on national biologic therapies (BIOGEAS, RABBIT, BSRBR-RA, BIOBADAVEN). More than 200 cases have so far been reported, all of them diagnosed on the basis of the histopathology or meeting the ACR/Chapel Hill criteria. Over 75 % of the cases were females with a mean age of 48 ± 5 years. More than 50 % had rheumatoid arthritis. Most of the biologics-associated vasculitis developed in 90 ± 31 days. Complete resolution in almost 75 % of the cases was observed upon treatment discontinuation; however, steroid therapy was indicated for all patients and one death was recorded. The use of cyclophosphamide, rituximab or plasma exchange was reserved for the most severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.